EAHP represents over 29,000 hospital pharmacists across 36 member countries. EAHP represents and develops the hospital pharmacy profession within Europe in order to ensure the continuous improvement of care and outcomes for patients in the hospital setting. This is achieved through science, research, education, practice, as well as sharing best-practice and responsibility with other healthcare professionals.
The EAHP Board, elected for three-year terms, oversees the association’s activities. Comprising directors responsible for core functions, it meets regularly to implement strategic goals. Supported by EAHP staff, the Board controls finances, coordinates congress organization, and ensures compliance with statutes and codes of conduct.
The EAHP staff supports the Board in executing EAHP’s mission. The Staff assists in financial management, events organisations, policy activities and all EAHP projects. The EAHP staff works closely with EAHP’s members and ensures the effective communication all relevant stakeholders.
The first member countries were Belgium, Britain, Denmark, France, the Federal Republic of Germany and The Netherlands in 1972. EAHP has now 36 EAHP members and 2 Associate Members. EAHP is open to countries members of the Council of Europe and since 2022 to organisations representing the interests of hospital pharmacists from outside the Council of Europe (Associate Membership)
EAHP’s structure is also composed by different standing committes: EAHP Scientific Committee, EAHP Education Executive Committee and the EAHP CTF Steering Committee.
At EAHP, we are committed to transparency in our governance, ethical standards, and funding practices. This section provides open access to our foundational documents, including the EAHP Statutes, Code of Conduct, and Funding Sources. By sharing these resources, we aim to uphold accountability and foster trust with our members, partners, and the public.
Keep up with all EAHP’s events and webinars. Contact the team at info@eahp.eu should you have any questions about upcoming events or activities.
Here you can find all upcoming events organised by EAHP and by all its members and associate members. Do not hesitate to contact the events team at events@eahp.eu should you have any questions about the organisation of these events.
Hospital pharmacists conduct a critical role in the care of patients in hospitals. Learn more about what they do here and in all the pages under Hospital Pharmacy practice and Policy.
Self-Assessment
SILCC
Closed SIGs
EAHP brings together experts from many areas of hospital pharmacy practice providing and highlighting good local sustainable practices as that can be up-scaled and shared with other countries. The EAHP Working Group on Sustainability has the aim of reducing the environmental burden of the hospital pharmacy services.
The European Association of Hospital Pharmacists (EAHP), and its 36 member country platforms are creating a Common Training Framework for the hospital pharmacy education in Europe. The goal of this project is to allow the free movement of hospital pharmacists within the European Union.
The European Association of Hospital Pharmacists (EAHP) and the European Society of Clinical Pharmacy (ESCP) have collaboratively developed the Oath to Society. The Oath to Society is all encompassing and acts as a contract for excellence in providing compassionate patient care, working as part of the healthcare team and advancing the pharmacy profession, and showcasing how clinical and hospital pharmacists work every day
A day created to highlight the importance and to celebrate the work done by hospital pharmacies. This day celebrates all hospital pharmacy teams.
Catch up with EAHP’s press releases
Find all EAHP relevant publication like the EAHP Surveys, annual reports and the history books.
The European Journal of Hospital Pharmacy (EJHP) is the only official journal of the European Association of Hospital Pharmacists (EAHP) and is committed to advancing the science, practice and profession of hospital pharmacy. As the premier communication platform for hospital pharmacists worldwide, EJHP is a major source for continuing education as well as updates on advances in the practice and standard of pharmaceutical care for patients.
When EAHP and Hospital pharmacists appear in the news.
EAHP publishes a monthly EU monitor with updates about the latest EAHP initiatives and information relevant for the hospital pharmacy profession.
Sponsor Channel
The Sponsor Channel is designed to maximise visibility and engagement, allowing sponsors to connect with the hospital pharmacy community and partners in a dynamic and interactive environment. From product demonstrations to networking sessions, the Sponsor Channel offers a range of opportunities for sponsors to showcase their offerings and generate leads in the new EAHP Website.
The EAHP EU Monitor is a regular round up of news relevant to hospital pharmacy in Europe.
Are you interested in advancing your skills linked to management, biosimilars, medicines shortage, anticoagulants, drug monitoring or procurement? Sign up for an Open Learning Course of the European Association of Hospital Pharmacists (EAHP). Created in spring 2018, EAHP’s Open Learning Course environment offers ten different open learning courses, ranging from 1.5-hour training on specific topics to 5-hour in-depth courses.
Hospital pharmacists and other interested healthcare professionals can choose from the following courses:
EAHP is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. Participants of the open learning courses will be entitled ACPE credits. These credits can be obtained after the completion of the course and a short survey.
Access EAHP’s Open Learning courses via the following LINK
Only three weeks are left until this year’s European Antibiotic Awareness Day (EAAD) and the start of the World Antimicrobial Awareness Week (WAAW). Get ready to show the world how you raise awareness about antimicrobial resistance (AMR) and preserve antimicrobials in times of COVID-19.
EAAD is a European health initiative coordinated by European Centre for Disease Prevention and Control (ECDC). It provides a platform and support for national campaigns on the prudent use of antibiotics in the EU/EEA and takes place each year across Europe on 18 November. Due to the COVID-19 pandemic, EAAD will this year be marked with a digital event and campaign.
This year’s EAAD will focus on the theme: “In times of COVID-19, don’t forget about antimicrobial resistance. Stay united to preserve antimicrobials.”. Healthcare professionals around Europe are encouraged to produce social media content around prudent use of antibiotics that include the following hashtags: #EAAD, #AntibioticResistance, #Antibiotics & #KeepAntibioticsWorking. A global Twitter storm is scheduled for the 18th of November at 17.00 CET. At that time organisations from around the globe will tweet about #AntibioticResistance and #WAAW to raise awareness of the issue. If you wish to participate, make sure to post this through your Twitter account at that time or during the day, together with hashtags that are relevant for you.
Learn more about EAAD 2021 HERE
Learn more about WAAW 2021 HERE
A new draft monograph, Oxygen (98 per cent) (3098), has been published for comment by the European Directorate for the Quality of Medicines & HealthCare (EDQM). The deadline for comments on the new monograph is 31 December 2021.
This draft monograph is the outcome of a thorough examination of the substantial response to the request for feedback issued in April 2020 and which prompted lively and constructive discussions with regulatory experts in the field, as well as a series of dedicated European Pharmacopoeia (Ph. Eur.) expert meetings.
The input representing different standpoints from a diverse range of stakeholders, including regulators, hospital pharmacists, industry representatives (gas producers and producers of oxygen generating equipment) and academics, allowed participants to approach the topic with the highest level of expertise. Contributions from all users and interested parties via Pharmeuropa on Ph. Eur. texts published for consultation is of fundamental importance to maintaining the Ph. Eur. – which is a legal standard in Europe – up-to-date and fit for purpose.
Learn more HERE
Access this quarter’s issue of Pharmeuropa (33.4) HERE
October marks the beginning of a new influenza season. During the 2021 Flu Awareness Week, the Coalition for Vaccination has launched a Statement via which European healthcare professionals encourage people, especially those belonging to an at-risk group, to adequately protect themselves from potentially serious illness by getting an influenza vaccine also this year.
In any given year, 5.15% of the population is affected by influenza, and every year there are 3.5 million cases of severe influenza and around 650.000 deaths globally. This represents a significant burden on people’s health, healthcare systems and economies. Vaccination remains the most effective measure to prevent severe influenza outcomes as highlighted in the Influenza Statement of the Coalition for Vaccination.
Also, the WHO/Europe launched its annual Flu Awareness Campaign to increase influenza vaccination uptake among groups of people that are at the greatest risk of experiencing severe outcomes due to infection. These groups are older people aged over 65 years, pregnant women, people with underlying health conditions, and children under 5 years of age. Because healthcare workers can be exposed to influenza through their line of work and because they are so essential to the COVID-19 pandemic response, they are also a key target group for this year’s campaign. The 2021 2022 influenza season will be the second in which influenza and COVID-19 have the potential to co-circulate.
The Coalition for Vaccination brings together European associations of healthcare professionals and relevant student associations in the field. It was convened by the European Commission in 2019 with an aim to support delivering accurate information to the public, combating myths around vaccines and vaccination, and exchanging best practices on vaccination.
Read the Influenza Statement HERE
Read the WHO/Europe Q&A on flu in the context of COVID-19 HERE
Medical devices play a fundamental role in the treatment of patients across Europe. Linked to the new medical devices Regulation (MDR) and in vitro diagnostic medical devices Regulation (IVDR), the European Commission provides on a regular basis a range of guidance documents to assist stakeholders in implementing the MDR and the IVDR. In October, guidance on the classification of medical devices, an update of the Helsinki Procedure and questions and answers on re-packaging and re-labelling activities were issued. In addition, a proposal for amending the roll-out of the IVDR was released.
On the 14th of October, the Commission issued a proposal for a progressive roll-out of IVDR. The aim of the proposed Regulation, which needs to be adopted by the European Parliament and the Council, is to smooth the transition from the current Directive 98/79/EC to the new Regulation (EU) 2017/746 in order to prevent disruption in the supply of essential in vitro diagnostic medical devices.
The Medical Device Coordination Group (MDCG) has put together a set of guidelines on the classification of medical devices, with information on the purpose and practical relevance of classification, how to carry out classification and the application of classification rules. The guidelines also contain a general explanation of the rules and of practical issues that arise, along with more in-depth explanations of individual rules. Linked to re-packaging and re-labelling obligations introduced by Article 16(2) to (4) under the MDR and the IVDR, the MDCG has created a set of questions and answers seeking to address some of the most common queries.
An updated version has been made available of the system agreed upon at the Medical Device Competent Authorities Meeting in Helsinki (Helsinki Procedure) in October 2002. The purpose of the system is to allow consultation among competent authorities on borderline and classification issues concerning medical devices and to ensure that the agreements are reflected in the Manual on Borderline and Classification for Medical Devices.
Read all about the progressive roll-out of IVDR HERE
Access the guidance on the classification of medical devices HERE
Read the Q&A on re-packaging and re-labelling activities HERE
Learn more about the Helsinki Procedure for borderline and classification under MDR/IVDR HERE
As part of her PhD project in clinical pharmacy, a member of the German Society of Hospital Pharmacists has put together a survey in order to demonstrate the benefits of a ward pharmacist in oncology and thus help to increase the patient’s therapeutic safety. The project puts a specific focus on interprofessional collaboration of ward pharmacists, doctors and nursing in oncology.
To assess the impact of possible improvements and to get the most comprehensive picture possible, it is necessary to determine the current situation throughout Europe. For representative data collection, only one answer from each hospital pharmacy is allowed. Your information will be handled strictly confidential and the results will only be published anonymously. Responses can be shared until 15 December 2021. Participation only takes a few minutes and aims also at supporting pharmacists in clinics without a cytostatics department.
Access the survey via the following LINK
EJHP: Enjoy reading the November issue
The latest issue of the European Journal of Hospital Pharmacy (EJHP) is available. The November issue features original research linked to clinical pharmacy services in Germany, the availability of age-appropriate paediatric formulations in the Netherland, the development of a sterile morphine hydrogel for the local treatment of painful skin ulcers and intravenous drug use in neonatal intensive care units. The three case reports included in this edition of the EJHP are looking at the successful treatment of interstitial pneumonitis with anakinra in a patient with adult-onset Still’s disease, the dramatic improvement of bullous pemphigoid with omalizumab in an elderly patient and a patient with ulcerative colitis treated with a combination of vedolizumab and tofacitinib.
Read the November issue HERE
[EAHP Statement Corner]
Since March 2018 EAHP has supported the implementation of the European Statements of Hospital Pharmacy with a self-assessment tool (SAT). EAHP’s SAT helps pharmacies across Europe to understand the level of Statement implementation. To ensure that as many hospital pharmacists as possible can use the SAT, different language versions (Czech, English, French, German, Greek, Hungarian, Italian, Polish, Portuguese, Romanian, Serbo-Croatian, Spanish and Turkish) have been made available. Talk to your chief pharmacist and encourage him/her to work with the SAT. In case you are the head of the pharmacy get your team together and complete your assessment today with the help of the SAT.
Learn more about SAT HERE
To assist its member associations and individual hospital pharmacists in this critical time with the provision of the best possible care for patients, EAHP has decided to gather and make available information on COVID-19 relevant for the hospital pharmacy profession.
Access the Resource Centre HERE
Ensuring that patients receive the medication they need to improve their health and to prevent and cure diseases is the key topic of EAHP’s Position Paper on Access to Medicines. Given that growing healthcare expenditure has become a problem for many European countries that also affects patients who are increasingly faced with avoidable accessibility and affordability issues, EAHP has chosen to look at the barriers to access and enablers that could help improve it.
Lack of purposeful procurement practices, national pricing and reimbursement policy choices jeopardising patients’ adequate access, medicine shortages and the unavailability in certain markets that are leading to inequity between Member States are the main barriers identified in the position. For the provision of affordable medicines of good quality that are given in a timely manner to patients, EAHP advocates for breaking down these barriers to treatment access and calls for uptake of enablers that promote and safeguard the access of patients to both new life-saving medicines and older, essential medicines must be increased. Enablers mentioned refer to health technology assessments (HTAs), including common reports at EU level, collaboration and best practice sharing on pricing and reimbursement, increasing the use of prevention measures and fostering innovation and research
To achieve an equilibrium between the barriers and the enablers to treatment access, the following has been put forward by EAHP:
In relation to the developments linked to the European Health Union aided by the implementation of the Pharmaceutical Strategy, EAHP underlined its commitment to working together with the European institutions and other stakeholders by giving a voice to access issues that otherwise might be forgotten.
Read the Position Paper on Access to Medicines HERE
European Commission – Public consultation on the revision of the general pharmaceutical legislation
This public consultation aims to collect views of stakeholders and the general public in order to support the evaluation of the existing general pharmaceutical legislation and the impact assessment of its revision. It builds further on the public consultation conducted for the preparation of the pharmaceutical strategy for Europe.
Deadline – 21st December 2021
Access the consultation HERE
